Abstract:Objective To investigate the associations of midlife diet quality with incident dementia and brain structure. Design Population-based prospective study and cross-sectional study. Setting UK Biobank. Participants In total, 187,783 participants (mean age 56.8 years, 54.9% women) who completed the 24-hour recall dietary questionnaire were included in the prospective study. A subgroup of 25,380 participants (mean age 55.7 years, 52.9% women) with brain structure data were included in the cross-sectional study. Main exposure and outcome measures Cox proportional hazards models and linear regression models were used to examine the associations of seven diet quality scores, i.e., hPDI (Healthful Plant-based Diet index), MDS (Mediterranean Diet score), aMED (alternate Mediterranean diet), RFS (Recommended Food Score), DASH (Dietary Approaches to Stop Hypertension), MIND (Mediterranean-DASH Intervention for Neurodegenerative Delay diet) and AHEI-2010 (the Alternative Healthy Eating Index-2010), with incident dementia and brain structure (estimated using magnetic resonance imaging), respectively. Results During a total follow-up of 1,969,993 person-years, 1,363 (0.73%) participants developed dementia. Higher diet quality scores (except for hPDI) were consistently associated with a lower incidence risk of dementia (all P for trend<0.001). For instance, for RFS, the hazard ratios of the intermediate tertile group and the highest tertile group relative to the lowest tertile group were 0.85 (95% confidence interval [95%CI]=0.75 to 0.97) and 0.70 (95%CI=0.61 to 0.81), respectively. Moreover, higher diet quality scores were significantly associated with larger regional brain volumes including volumes of grey matter (GM) in the parietal and temporal cortex and volumes of the hippocampus and thalamus. For instance, higher RFS was associated with larger volumes of GM in the postcentral gyrus (β=16.05±4.08, P<0.001) and the hippocampus (β=5.87±1.26, P<0.001). A series of sensitivity analyses confirmed the main results. Conclusion Greater adherence to MDS, aMED, RFS, DASH, MIND, and AHEI-2010 were individually associated with lower risk of incident dementia and larger brain volumes in specific regions. This study shows a comprehensive picture of the consistent associations of midlife diet quality with dementia risk and brain health, providing mechanistic insights into the role of healthy diet in the prevention of dementia. What is already known on this topic 1. Previous prospective studies and meta-analyses suggested significant associations between a few diet quality scores (i.e., MDS, DASH, MIND, and AHEI-2010) and the risk of dementia in different populations; however, the results did not reach agreement. 2. Nutrient intakes or very few diet quality scores have been demonstrated to be associated with brain volumes derived from MRI. There is limited research on the associations of various diet quality scores with the risk of dementia and brain structures in the same population. What this study adds 1. Greater adherence to MDS, aMED, RFS, DASH, MIND, and AHEI-2010, but not hPDI was individually associated with lower risks of incident dementia. 2. Greater adherence to MDS, aMED, DASH, and AHEI-2010, especially RFS, was individually associated with larger brain volumes in special regions (e.g., parietal and temporal cortex, and hippocampus). 3. This study shows a comprehensive picture of the consistent associations of midlife diet quality with dementia risk and brain health, providing mechanistic insights into the role of healthy diets in the prevention of dementia. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This research was supported by a grant from the National Natural Science Foundation of China (82171584), the Fundamental Research Funds for the Central Universities, Key Laboratory of Intelligent Preventive Medicine of Zhejiang Province (2020E10004), and Zhejiang University Global Partnership Fund (188170-11103). This work was also supported by the Claude D. Pepper Older Americans Independence Center at Yale School of Medicine, funded by the National Institute on Aging (P30AG021342) and the Yale Alzheimer's Disease Research Center, funded by the National Instititue on Aging (P30AG066508). The funders had no role in the study design; data collection, analysis, or interpretation; in the writing of the report; or in the decision to submit the article for publication. The funders had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study used ONLY openly available human data that were originally located at: <http://www.ukbiobank.ac.uk/register-apply>. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes All data produced are available online at <http://www.ukbiobank.ac.uk/register-apply>. <http://www.ukbiobank.ac.uk/register-apply>.

Abstract 54: Newly Initiation of Antihypertensive Medication on Reduction of Incident Dementia: Emulation of Target Trials Based on the Health and Retirement Study

Initiation of Antihypertensive Medication from Midlife on Incident Dementia: The Health and Retirement Study.

Target trial emulation using cohort studies: estimating the effect of antihypertensive medication initiation on incident dementia

Use of Antihypertensives, Blood Pressure, and Estimated Risk of Dementia in Late Life: An Individual Participant Data Meta-Analysis

Physical activity initiated from midlife on risk of dementia and cognitive impairment: The Health and Retirement Study

Antihypertensive medications and dementia in older adults with hypertension

Blood Pressure, Antihypertensive Use, and Late-Life Alzheimer and Non-Alzheimer Dementia Risk: An Individual Participant Data Meta-Analysis

Trajectories of Cognitive Decline Before and After New-onset Hypertension

Randomised controlled decentralised feasibility trial of a fixed low-dose combination antihypertensive drug strategy to attenuate cognitive decline in high-risk adults

Risk of Dementia During Antihypertensive Drug Therapy in the Elderly

Antihypertensive medication and dementia risk in patients with hypertension: A nationwide population-based study

Effect of Population-Level Blood Pressure Treatment Strategies on Cardiovascular and Cognitive Outcomes

Antihypertensive medication classes and risk of incident dementia in primary care patients: a longitudinal cohort study in the Netherlands

Effect of Age Range on Power for a Clinical Trial Investigating the Effect of Intensive Systolic Blood Pressure Control on White Matter Hyperintensity Volume Accumulation

Associations of Midlife Diet Quality with Incident Dementia and Brain Structure: Findings from the UK Biobank Study

Midlife Modifiable Risk Factors for Dementia: A Systematic Review and Meta-analysis of 34 Prospective Cohort Studies

Hypertension and Mild Cognitive Impairment: State-of-the-Art Review

Later onset of hypertension increased the risk of dementia in Mild Cognitive Impairment in community

Antihypertensive Treatment and Prevention of Stroke and Dementia

Angiotensin Receptor Blockers Are Associated With a Lower Risk of Progression From Mild Cognitive Impairment to Dementia

Blood pressure targets for prevention of cognitive decline in patients with diabetes and hypertension: Design of the Blood Pressure Control Target in Diabetes (BPROAD) Cognitive Study